Drugs / CD19/BCMA CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05030779 | Sep 2021 → Mar 2022 | systemic lupus erythematosus | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05030779 ↗ |
| Action | Deplete | “This research focuses on CAR-T cells killing B cells.” NCT05030779 ↗ |
| Modality | Cell therapy | “anti-CD19 and anti-BCMA chimeric antigen receptor (CAR) T cells” PMID 40993243 ↗ Sep 2025 |
| Route | Intravenous | “by intravenous infusion” NCT05030779 ↗ |
| Target | CD19 | “motivating dual CD19 and BCMA targeting” PMID 40993243 ↗ Sep 2025 |